Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure

25 de julho de 2026 atualizado por: Rehab Hassan Abdel-hafiz Hassan, Assiut University

Evaluation of Novel Scores for Prediction of Outcomes in Patients With Acute-on-Chronic Liver Failure

Acute-on-chronic liver failure (ACLF) is a serious condition where a patient with long-term liver disease suddenly experiences severe liver worsening and failure of other organ systems, such as the kidneys or lungs. ACLF is associated with a high risk of short-term death, making early and accurate prediction of patient outcomes essential for guiding medical decisions.

Conventional scoring systems, such as the Child-Pugh and Model for End-Stage Liver Disease Sodium (MELD-Na) scores, are widely used to assess liver disease severity. However, these traditional models may not fully capture the intense systemic inflammation and multiorgan failure characteristic of ACLF. Recently, novel prognostic scoring models, specifically the CLIF-C ACLF-D score and the MELD-complication score, have been developed to better predict patient outcomes by integrating markers of inflammation, organ dysfunction, and clinical complications.

This study aims to evaluate and validate the clinical usefulness of these novel scoring models compared to conventional scores in predicting in-hospital and 28-day mortality among patients admitted with ACLF.

Participants enrolled in this prospective observational study will be recruited from the Intensive Care Unit (ICU) of the Tropical Medicine and Gastroenterology Department at Al-Rajhi University Hospital. Upon admission, participants will undergo routine clinical examinations, laboratory testing, and imaging. The various risk scores will be calculated at baseline. Participants will be monitored throughout their hospital stay, and their survival status will be followed for 28 days after admission to compare the accuracy of each scoring system.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

Acute decompensation in liver cirrhosis is the primary cause of hospitalization among cirrhotic patients. Acute-on-chronic liver failure (ACLF) represents a distinct, severe clinical entity characterized by systemic inflammation, single- or multiple-organ failures, and high short-term mortality. While traditional scoring systems like the Child-Pugh and Model for End-Stage Liver Disease Sodium (MELD-Na) scores are routinely utilized, they may fail to capture the complex inflammatory response and multiorgan involvement inherent to ACLF.

To improve prognostic estimation, novel predictive tools, including the CLIF-C ACLF-D score and the MELD-complication score, have been introduced, incorporating inflammatory parameters and complication markers. Validation of these prognostic models across distinct patient populations is necessary prior to broad implementation. This study evaluates the prognostic performance of these novel models in patients with ACLF admitted to the Intensive Care Unit (ICU).

All enrolled participants will undergo systematic evaluation upon admission:

  1. Clinical and Demographic Assessment: Full patient history (demographics, etiology of underlying chronic liver disease, previous episodes of decompensation, drug history) and comprehensive physical examination (vital signs, grade of hepatic encephalopathy, jaundice, asterixis, edema, and clinical signs of infection or ascites/pleural effusion).
  2. Laboratory Diagnostics: Complete blood count with differential, liver function tests (total and direct bilirubin, serum albumin), renal function parameters (serum creatinine, blood urea nitrogen), coagulation profile (prothrombin time, INR), serum electrolytes (sodium, potassium), C-reactive protein (CRP), arterial blood gas analysis, viral hepatitis markers (HBsAg, anti-HCV), ascitic fluid analysis (if applicable), and biological cultures from suspected infectious foci.
  3. Imaging: Abdominal ultrasonography (evaluating hepatic architecture, portal vein parameters, splenic dimensions, collateral circulation, biliary structure, renal status, ascites) and chest radiography.
  4. Scoring Calculation: Baseline risk scores-including Child-Pugh, MELD-Na, CLIF-C OF, CLIF-C ACLF, CLIF-C ACLF-D, and MELD-complication scores-will be calculated at admission using standard mathematical formulas and validated online platforms.

Participants will be followed throughout their hospital stay and up to 28 days following admission. Survival outcomes will be confirmed in-hospital or post-discharge via telephone follow-up or clinical visits.

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

N/D

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients diagnosed with Acute-on-Chronic Liver Failure (ACLF) according to the EASL-CLIF diagnostic criteria who are admitted to the Intensive Care Unit (ICU) of the Tropical Medicine and Gastroenterology Department at Al-Rajhi University Hospital.

Descrição

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Diagnosed with Acute-on-Chronic Liver Failure (ACLF) fulfilling the diagnostic criteria according to EASL-CLIF.
  • Admitted to the Intensive Care Unit (ICU) of the Tropical Medicine and Gastroenterology Department, Al-Rajhi University Hospital.

Exclusion Criteria:

  • Patients with hepatocellular carcinoma.
  • Patients with advanced extrahepatic malignancy.
  • Pregnant females.
  • Patients younger than 18 years old.
  • Patients with incomplete clinical or laboratory data.
  • Patients or first-degree relatives refusing participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
ACLF Patients
Patients aged 18 years or older diagnosed with Acute-on-Chronic Liver Failure (ACLF) according to EASL-CLIF criteria and admitted to the Intensive Care Unit of the Tropical Medicine and Gastroenterology Department at Al-Rajhi University Hospital. All patients will undergo full clinical, laboratory, and radiological evaluations at baseline, followed by calculation of novel (CLIF-C ACLF-D, MELD-complication) and conventional (Child-Pugh, MELD-Na, CLIF-C ACLF) prognostic scores to predict short-term outcomes.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
28-Day All-Cause Mortality Rate
Prazo: 28 days post-hospital admission
Percentage of participants with Acute-on-Chronic Liver Failure (ACLF) who die from any cause within 28 days following hospital admission. Survival status will be evaluated during the hospital stay and confirmed post-discharge via clinic visits or telephone follow-up.
28 days post-hospital admission

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
In-Hospital All-Cause Mortality Rate
Prazo: From date of hospital admission up to hospital discharge, assessed up to 28 days
Percentage of participants with Acute-on-Chronic Liver Failure (ACLF) who die from any cause during their hospital stay.
From date of hospital admission up to hospital discharge, assessed up to 28 days
Prognostic Performance of the CLIF-C ACLF-D Score for 28-Day Mortality
Prazo: Baseline (day 1 of admission) up to 28 days
Predictive accuracy of the novel CLIF-C ACLF-D score measured by the Area Under the Receiver Operating Characteristic Curve (AUROC) to predict 28-day all-cause mortality.
Baseline (day 1 of admission) up to 28 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de agosto de 2026

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

25 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de julho de 2026

Primeira postagem (Real)

29 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

29 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Predicting Outcomes in ACLF

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .